RPB-supported researchers have published new findings indicating they are on the verge of developing a better treatment than the anti-VEGF injections currently used for macular degeneration. In studies, a class of drugs known as MDM2 inhibitors proved highly effective at regressing the abnormal blood vessels responsible for the vision loss associated with the disease. The new approach would not require repeated injections.
September 16, 2013
|General Info||Research Scientists & Grantees||Eye Care Specialists||Donors & Partners|